Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap?
Backgrounds Streptococcus pneumoniae cause serious disease including pneumonia, meningitis and bacteremia and mortality is seen most in developing countries. The aim of the study was to determine if the reduction in IPD and pneumonia rates were similar in developed and developing countries after the...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
LLC "Publishing House OKI"
2020-05-01
|
| Series: | Антибиотики и Химиотерапия |
| Subjects: | |
| Online Access: | https://www.antibiotics-chemotherapy.ru/jour/article/view/698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849244532678328320 |
|---|---|
| author | R. Kornetsky D. Greenberg O. Falup-Pecurariu |
| author_facet | R. Kornetsky D. Greenberg O. Falup-Pecurariu |
| author_sort | R. Kornetsky |
| collection | DOAJ |
| description | Backgrounds Streptococcus pneumoniae cause serious disease including pneumonia, meningitis and bacteremia and mortality is seen most in developing countries. The aim of the study was to determine if the reduction in IPD and pneumonia rates were similar in developed and developing countries after the introduction of the pneumococcal conjugated vaccine and to determine changes in the disparities of these diseases rates in these countries. Methods. Literature searches were conducted by using the PubMed database and Google scholar. The main criterion for selection was that the studies compare incidence of IPD or pneumonia in children pre and post PCV7, PCV10, or PCV13 vaccine introduction. Only published articles that described the incidence rate of IPD or pneumonia with quantitative data were fully reviewed in detail. Results. A total of 22 articles were full-text original publications and one was a review article. Within 3 years of PCV introduction in the United States, all-cause IPD dropped from 98.7/100,000 to 20/100,000 children |
| format | Article |
| id | doaj-art-417bd6d75d2e448e91baf0efd4e2d74e |
| institution | Kabale University |
| issn | 0235-2990 |
| language | Russian |
| publishDate | 2020-05-01 |
| publisher | LLC "Publishing House OKI" |
| record_format | Article |
| series | Антибиотики и Химиотерапия |
| spelling | doaj-art-417bd6d75d2e448e91baf0efd4e2d74e2025-08-20T03:59:08ZrusLLC "Publishing House OKI"Антибиотики и Химиотерапия0235-29902020-05-016111-125667697Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap?R. Kornetsky0D. Greenberg1O. Falup-Pecurariu2Университет им. Бен-Гуриона НегевУниверситетский медицинский центр СорокаУниверситет ТрансильванииBackgrounds Streptococcus pneumoniae cause serious disease including pneumonia, meningitis and bacteremia and mortality is seen most in developing countries. The aim of the study was to determine if the reduction in IPD and pneumonia rates were similar in developed and developing countries after the introduction of the pneumococcal conjugated vaccine and to determine changes in the disparities of these diseases rates in these countries. Methods. Literature searches were conducted by using the PubMed database and Google scholar. The main criterion for selection was that the studies compare incidence of IPD or pneumonia in children pre and post PCV7, PCV10, or PCV13 vaccine introduction. Only published articles that described the incidence rate of IPD or pneumonia with quantitative data were fully reviewed in detail. Results. A total of 22 articles were full-text original publications and one was a review article. Within 3 years of PCV introduction in the United States, all-cause IPD dropped from 98.7/100,000 to 20/100,000 childrenhttps://www.antibiotics-chemotherapy.ru/jour/article/view/698пневмококковые вакциныдетипневмонияинвазивная пневмококковая инфекциязаболеваемость |
| spellingShingle | R. Kornetsky D. Greenberg O. Falup-Pecurariu Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap? Антибиотики и Химиотерапия пневмококковые вакцины дети пневмония инвазивная пневмококковая инфекция заболеваемость |
| title | Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap? |
| title_full | Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap? |
| title_fullStr | Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap? |
| title_full_unstemmed | Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap? |
| title_short | Disparities in Effectiveness of Pneumococcal Vaccine in Industrialized and Developing Countries: Is Vaccination Closing the Gap? |
| title_sort | disparities in effectiveness of pneumococcal vaccine in industrialized and developing countries is vaccination closing the gap |
| topic | пневмококковые вакцины дети пневмония инвазивная пневмококковая инфекция заболеваемость |
| url | https://www.antibiotics-chemotherapy.ru/jour/article/view/698 |
| work_keys_str_mv | AT rkornetsky disparitiesineffectivenessofpneumococcalvaccineinindustrializedanddevelopingcountriesisvaccinationclosingthegap AT dgreenberg disparitiesineffectivenessofpneumococcalvaccineinindustrializedanddevelopingcountriesisvaccinationclosingthegap AT ofaluppecurariu disparitiesineffectivenessofpneumococcalvaccineinindustrializedanddevelopingcountriesisvaccinationclosingthegap |